This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JAMES C. M. CHAN, MD
Department of Pediatrics Box 646 Children's Medical Center Richmond, VA 23298-0001

VERNON M. CHINCHILLI, PHD
Department of Biostatistics Box 32 Medical College of Virginia Richmond, VA 23298-0001

Am J Dis Child. 1988;142(1):14.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—Several lines of evidence have recently indicated the defective 1-hydroxylase system in X-linked hypophosphatemia. Thus, the rational therapeutic approach is to use 1,25-dihydroxyvitamin D together with phosphate supplementations. In certain patients, the therapeutic response has been very dramatic, especially in growth velocity indexes, as noted in our article. However, other patients fail to gain in height despite such therapy. Using the Z score of linear growth, we were unable to show significant differences in linear growth due to the heterogeneity of the therapeutic response. There are other effects and complications of the use of 1,25-dihydroxyvitamin D that our group and others are working on, and we still hope to convince Dr Stickler to use 1,25-dihydroxyvitamin D and phosphate supplementation in the not-too-distant future. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?